American Society of Pediatric Hematology/Oncology **Legislative Tracking Chart** 115th Congress – (2017-2018) *Updated: July 20, 2017*

Bill Title and Description	Bill Number/Sponsor	Co-Sponsors	Status	Get Involved
Childhood Cancer Survivorship, Treatment, Access, and Research (STAR) Act To maximize discovery, and accelerate development and	H.R. 820 Michael McCaul (R- TX)	251: 147 D, 104 R	Introduced 02/02/2017; referred to Energy & Commerce Subcommittee on Health	Take Action
availability, of promising childhood cancer treatments, and for other purposes	S. 292 Jack Reed (D-RI)	20: 10 R, 9 D, 1 I	Introduced 02/02/2017; referred to Health, Education, Labor, Pensions Committee	Take Action
Research to Accelerate Cures and Equity (RACE) for Children Act To amend the Federal Food, Drug, and Cosmetic Act to establish a	H.R. 1231 Michael McCaul (R- TX)	28: 18 D, 10 R	Introduced 02/27/2017; referred to Energy & Commerce Subcommittee on Health	Take Action
program to increase the development of new drugs to treat pediatric cancers, and for other purposes.	S. 456 Michael Bennet (D-CO)	3: 2 R, 1 D	Introduced 02/27/2017; referred to Health, Education, Labor, Pensions Committee	Take Action
Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act To amend the Public Health Service Act to reauthorize a sickle cell disease prevention and treatment demonstration program and to provide for sickle cell disease research, surveillance, prevention, and treatment.	H.R. 2410 Danny Davis (D-IL)	2: 1 D, 1 R	Introduced 05/11/2017; referred to Energy & Commerce Subcommittee on Health; Subcommittee Consideration and Mark-up Session Held; Forwarded by Subcommittee to Full Committee by Voice Vote; Ordered to be Reported by Voice Vote.	
	No Senate bill			
Patient Experience in Research Act To direct the Secretary of Health and Human Services to carry out a	H.R. 2244 Leonard Lance (R-NJ)	3: 3 D	Introduced 04/28/2017; referred to Energy & Commerce Subcommittee on	

pilot project under which no more			Health	
than 3 sponsors agree to evaluate	No Senate bill			
the psychological and social distress				
experienced by patients				
participating in a clinical trial,				
conducted by the respective				
sponsor, of a drug or biological				
product that is intended to treat a				
serious or life-threatening disease or				
condition, and for other purposes.				
Sarah Grace-Farley-Kluger Act	H.R. 1560	13: 7 R, 6 D	Introduced 03/16/2017;	
To amend the Family and Medical	Paul Gosar (R-AZ)		referred to House	
Leave Act of 1993 to provide leave			Administration, Oversight and	
because of the death of a son or			Government Reform,	
daughter.			Education and the Workforce	
	S. 528	13: 12 D, 1 I	Introduced 03/06/2017	
	Jon Tester (D-MT)			
Trickett Wendler Right to Try Act	H.R. 878	42: 38 R, 4 D	Introduced 02/06/2017;	
of 2017	Andy Biggs (R-AZ)		referred to Energy &	
To authorize the use of unapproved			Commerce and Judiciary	
medical products by patients	H.R. 2368	3: 2 R, 1 D	•	
diagnosed with a terminal illness in	Brian Fitzpatrick (R-		Introduced 05/04/2017;	
accordance with State law, and for	PA)		referred to Energy &	
other purposes.			Commerce Subcommittee on	
			Health and Judiciary	
	S. 204	46: 43 R, 2 D,	Introduced 01/24/2017;	
	Ron Johnson (R-TX)	1 I	referred to Health, Education,	
			Pensions, Labor Committee	
Deferment for Active Cancer	H.R. 2976	13: 10 D, 3 R	Introduced 06/21/2017;	Take Action
<u>Treatment Act</u>	Illeana Ros-Lehtinen		referred to the House	
To amend the Higher Education Act	(R-FL)		Committee on Education and	
of 1965 to allow for the deferment of			the Workforce	

certain student loans during a		
period in which a borrower is		
receiving treatment for cancer.		